Cytomegalovirus (HHV-5) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Cytomegalovirus (CMV or HHV-5) is a contagious infection caused by a member of the herpes virus family. CMV is spread through saliva or urine. The symptoms of CMV include fever, pneumonia, weight loss, hearing, neurological and developmental problems. Exposure to direct contact with an infected surface or organism, weakened immune system and congenital factors are some predisposing factors of HHV-5.
The CMV pipeline drugs market research report provides comprehensive information on the therapeutics under development for CMV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for CMV and features dormant and discontinued projects.
CMV Pipeline Drugs Market Segmentation by Targets
Some of the targets of the CMV pipeline drugs market are Human Cytomegalovirus Envelope Glycoprotein B, Human cytomegalovirus 65 kDa Phosphoprotein, Human Cytomegalovirus Glycoprotein H, Serine/Threonine Protein Kinase UL97, DNA Polymerase, Human cytomegalovirus 45 kDa Immediate Early Protein 2, Human cytomegalovirus 55 kDa Immediate Early Protein 1, and Human Cytomegalovirus IE1 Protein among others. Human Cytomegalovirus Envelope Glycoprotein B leads this segment of the CMV pipeline drugs market.
CMV Pipeline Drugs Market Analysis, by Targets
For more CMV pipeline drugs market target insights, download a free report sample
CMV Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the CMV pipeline drugs market are Human Cytomegalovirus Envelope Glycoprotein B Inhibitor, Serine/Threonine Protein Kinase UL97 Inhibitor, DNA Polymerase Inhibitor, Human Cytomegalovirus Glycoprotein H Inhibitor, 70 kDa Ribosomal Protein S6 Kinase Inhibitor, CD3 Agonist, Envelope Protein M Inhibitor, Exportin 1 Inhibitor, and Human cytomegalovirus G Protein Coupled Receptor Homolog US28 Antagonist among others. Human Cytomegalovirus Envelope Glycoprotein B Inhibitor leads the CMV pipeline drugs market in terms of MoA.
CMV Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the CMV pipeline drugs market, download a free report sample
CMV Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the CMV pipeline drugs market are intravenous, intramuscular, oral, parenteral, intradermal, subcutaneous, and intravenous bolus. Intravenous leads the CMV pipeline drugs market in terms of RoA.
CMV Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the CMV pipeline drugs market, download a free report sample
CMV Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the CMV pipeline drugs market are Cell Therapy, Small Molecule, Monoclonal Antibody, Recombinant Vector Vaccine, Subunit Vaccine, Gene-Modified Cell Therapy, Antibody, and mRNA Vaccine among others. Cell Therapy leads the CMV pipeline drugs market in terms of molecule types.
CMV Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the CMV pipeline drugs market, download a free report sample
CMV Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the CMV pipeline drugs market are Merck & Co Inc, Helocyte Biosciences Inc, GSK plc, Moderna Inc, AlloVir Inc, Evrys Bio, Microbiotix Inc, Stadius Biopharma LLC, Abhelix LLC, and Acer Therapeutics Inc among others. Merck & Co Inc has the highest number of products under development.
Acer Therapeutics Inc: Acer Therapeutics Inc (Acer), is a Pharmaceutical company. It offers commercialize therapies for patients with serious rare diseases. Its pipeline product portfolio includes EDSIVO, for the treatment of vascular ehlers-danlos syndrome; ACER-001, a taste-masked, immediate-release formulation of sodium phenylbutyrate for urea cycle disorders (UCDs) and maple syrup urine disease (MSUD); osanetant, a neurokinin 3 receptor antagonist against induced vasomotor symptoms and emetine for infectious diseases. Acer uses a T-cell technology platform for the development of patient-specific T-cell therapies. The company operates manufacturing facilities, and research and development facilities in the US and Canada. Acer is headquartered in Newton, Massachusetts, the US.
CMV Pipeline Drugs Market Analysis, by Companies
To know more about the CMV pipeline drugs market companies, download a free report sample
CMV Pipeline Drugs Market Report Overview
Key Targets | Human Cytomegalovirus Envelope Glycoprotein B, Human cytomegalovirus 65 kDa Phosphoprotein, Human Cytomegalovirus Glycoprotein H, Serine/Threonine Protein Kinase UL97, DNA Polymerase, Human cytomegalovirus 45 kDa Immediate Early Protein 2, Human cytomegalovirus 55 kDa Immediate Early Protein 1, and Human Cytomegalovirus IE1 Protein |
Key Mechanisms of Action | Human Cytomegalovirus Envelope Glycoprotein B Inhibitor, Serine/Threonine Protein Kinase UL97 Inhibitor, DNA Polymerase Inhibitor, Human Cytomegalovirus Glycoprotein H Inhibitor, 70 kDa Ribosomal Protein S6 Kinase Inhibitor, CD3 Agonist, Envelope Protein M Inhibitor, Exportin 1 Inhibitor, and Human cytomegalovirus G Protein Coupled Receptor Homolog US28 Antagonist |
Key Routes of Administration | Intravenous, Intramuscular, Oral, Parenteral, Intradermal, Subcutaneous, and Intravenous Bolus |
Key Molecule Types | Cell Therapy, Small Molecule, Monoclonal Antibody, Recombinant Vector Vaccine, Subunit Vaccine, Gene-Modified Cell Therapy, Antibody, and mRNA Vaccine |
Key Companies | Merck & Co Inc, Helocyte Biosciences Inc, GSK plc, Moderna Inc, AlloVir Inc, Evrys Bio, Microbiotix Inc, Stadius Biopharma LLC, Abhelix LLC, and Acer Therapeutics Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of CMV.
- The pipeline guide reviews pipeline therapeutics for CMV by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in CMV therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates CMV therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for CMV
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for CMV.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the CMV pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Acer Therapeutics Inc
AlloVir Inc
AlphaVax Inc
Artemis Therapeutics Inc
Biotest AG
Chengdu Rongsheng Pharmaceutical Co Ltd
China Biologic Products Holdings Inc
China Immunotech Co Ltd
Citranvi Biosciences LLC
Cyrus Biotechnology Inc
Danuvius BioSciences
Evrys Bio
GSK plc
Helocyte Biosciences Inc
Hookipa Pharma Inc
Huinuo Biomedical Technology Co Ltd
iCELL Biotechnology Co Ltd
Immunetune BV
Karyopharm Therapeutics Inc
Lion TCR Pte Ltd
Memo Therapeutics AG
Merck & Co Inc
Microbiotix Inc
Moderna Inc
Nobelpharma Co Ltd
Okogen Inc
Phoenix Biotechnology Inc
Prosit Sole Biotechnology (Beijing) Co Ltd
Savoy Pharmaceuticals Inc
Shanxi Kangbao Biological Product Co Ltd
SL VaxiGen Inc
SpyBiotech Ltd
Stadius Biopharma LLC
Synklino ApS
Takeda Pharmaceutical Co Ltd
Trellis Bioscience Inc
VBI Vaccines Inc
Vichem Chemie Research Ltd
Viramatix Sdn Bhd
ViroKyne Therapeutics LLC
Zhuhai Trinomab Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the CMV pipeline drugs market?
Some of the targets of the CMV pipeline drugs market are Human Cytomegalovirus Envelope Glycoprotein B, Human cytomegalovirus 65 kDa Phosphoprotein, Human Cytomegalovirus Glycoprotein H, Serine/Threonine Protein Kinase UL97, DNA Polymerase, Human cytomegalovirus 45 kDa Immediate Early Protein 2, Human cytomegalovirus 55 kDa Immediate Early Protein 1, and Human Cytomegalovirus IE1 Protein.
-
What are the key mechanisms of action in the CMV pipeline drugs market?
Some of the mechanisms of action of the CMV pipeline drugs market are Human Cytomegalovirus Envelope Glycoprotein B Inhibitor, Serine/Threonine Protein Kinase UL97 Inhibitor, DNA Polymerase Inhibitor, Human Cytomegalovirus Glycoprotein H Inhibitor, 70 kDa Ribosomal Protein S6 Kinase Inhibitor, CD3 Agonist, Envelope Protein M Inhibitor, Exportin 1 Inhibitor, and Human cytomegalovirus G Protein Coupled Receptor Homolog US28 Antagonist.
-
What are the key routes of administration in the CMV pipeline drugs market?
The key routes of administration in the CMV pipeline drugs market are intravenous, intramuscular, oral, parenteral, intradermal, subcutaneous, and intravenous bolus.
-
What are the key molecule types in the CMV pipeline drugs market?
The molecule types in the CMV pipeline drugs market are Cell Therapy, Small Molecule, Monoclonal Antibody, Recombinant Vector Vaccine, Subunit Vaccine, Gene-Modified Cell Therapy, Antibody, and mRNA Vaccine.
-
Which are the leading companies in the CMV pipeline drugs market?
Some of the leading companies in the CMV pipeline drugs market are Merck & Co Inc, Helocyte Biosciences Inc, GSK plc, Moderna Inc, AlloVir Inc, Evrys Bio, Microbiotix Inc, Stadius Biopharma LLC, Abhelix LLC, and Acer Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.